β‐adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study
Open Access
- 17 June 2013
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 77 (1) , 190-200
Abstract
Aim: β‐adrenoceptor blockers have been used with caution in patients with obstructive lung diseases such as asthma or chronic obstructive pulmonary disease (COPD), due to the potentially increased airway reactivity and risk of bronchial obstruction. Cardioselective β‐adrenoceptor blockers have a more beneficial profile than non‐cardioselective β‐adrenoceptor blockers and can be safely prescribed to patients with both cardiovascular disease and COPD. We hypothesized that cardioselective β‐adrenoceptor blockers also affect pulmonary function.Methods: This study was performed within the Rotterdam Study, a prospective population‐based cohort study. Effects of cardioselective and non‐cardioselective β‐adrenoceptor blockers on pulmonary function were analysed using regression techniques with multivariable adjustment for potential confounders.Results: Current use of non‐cardioselective β‐adrenoceptor blockers was significantly associated with a lower forced expiratory volume in 1 s (FEV1) of −198 ml (95% CI −301, −96), with a lower forced vital capacity (FVC) of −223 ml (95% CI −367, −79) and with a decreased FEV1 : FVC of −1.38% (95% CI −2.74, −0.13%). Current use of cardioselective β‐adrenoceptor blockers was significantly associated with a lower FEV1 of −118 ml (95% CI −157, −78) and with a lower FVC of −167 ml (95% CI −222, −111), but did not affect FEV1 : FVC. After exclusion of patients with COPD, asthma and heart failure the effects of cardioselective β‐adrenoceptor blockers remained significant for FEV1 (−142 ml [95% CI −189, −96]) and for FVC (−176 ml [95% CI −236, −117]).Conclusion: In our study both non‐cardioselective and cardioselective β‐adrenoceptor blockers had a clinically relevant effect on both FEV1 and FVC. In contrast to cardioselective β‐adrenoceptor blockers, use of non‐cardioselective β‐adrenoceptor blockers was associated with a significantly lower FEV1 : FVC.Keywords
This publication has 31 references indexed in Scilit:
- Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary DiseaseJACC, 2010
- Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortalityCurrent Opinion in Pulmonary Medicine, 2010
- A Postmortem Analysis of Major Causes of Early Death in Patients Hospitalized With COPD ExacerbationChest, 2009
- Prevalence, Incidence, and Lifetime Risk for the Development of COPD in the ElderlyChest, 2009
- Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohortThorax, 2008
- Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint CommitteeThorax, 2007
- Heart Failure and cHronic Obstructive Pulmonary Disease: An Ignored Combination?European Journal of Heart Failure, 2006
- Minimal Clinically Important Differences in COPD Lung FunctionCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005
- Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly studyBritish Journal of Clinical Pharmacology, 1998
- Determinants of disease and disability in the elderly: The Rotterdam elderly studyEuropean Journal of Epidemiology, 1991